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Atherosclerosis is the main pathology behind most cardiovascular diseases. It is a chronic inflammatory dis-
ease characterized by the formation of lipid-rich plaques in arteries. Atherosclerotic plaques are initiated by
the deposition of cholesterol-rich LDL particles in the arterial walls leading to the activation of innate and
adaptive immune responses. Current treatments focus on the reduction of LDL blood levels using statins,
however the critical components of inflammation and autoimmunity have been mostly ignored as therapeu-
tic targets. The restoration of immune tolerance towards atherosclerosis-relevant antigens can arrest lesion
development as shown in pre-clinical models. In this review, we evaluate the clinical development of similar
strategies for the treatment of inflammatory and autoimmune diseases like rheumatoid arthritis, type
1 diabetes or multiple sclerosis and analyse the potential of tolerogenic vaccines for atherosclerosis and
the challenges that need to be overcome to bring this therapy to patients.
© 2020 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license.
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Atherosclerosis is the main underlying cause of acute cardiovascu-
lar events such as myocardial infarction or stroke [1]. Traditionally,
atherosclerosis has been primarily considered a pathology related to
dyslipidaemia, therefore lipid-lowering therapies such as statins
have been the mainstream option for prevention of cardiovascular
events. However, in recent years several lines of evidence have
highlighted the importance of the immune component of atheroscle-
rosis [2]. The development of an atherosclerotic lesion initiates with
the infiltration of lipoproteins, mainly low-density lipoproteins
(LDL), from the blood into the intima of the arteries. The infiltration
and accumulation of LDL particles into the arterial intima leads to the
chemical modification of some components of the lipoprotein and
the formation of modified LDL, mainly oxidized LDL (oxLDL). The
presence of oxLDL in the sub-endothelial space of the artery triggers
an inflammatory response that involves both the innate and the
adaptive arms of the immune system [3].
The initial accumulation of oxLDL leads to the over-expression of
adhesion molecules in endothelial cells, promoting the infiltration of
monocytes from the blood. These monocytes will differentiate into
macrophages, which phagocyte LDL particles and eventually become
foam cells, characterized by the presence of large cholesteryl esters
deposits in the cytoplasm and the secretion of pro-inflammatory
cytokines like IL-1b [4].Other innate immune cells such as dendritic cells (DCs) play an
important role in the development of the plaque. DCs, a subset of
antigen-presenting cells, are the link between the innate and the
adaptive immune responses. DCs in the atherosclerotic plaque
phagocyte antigens such us LDL from the environment, process them
and present small apoB100-derived peptides bound to Major Histo-
compatibility Complex (MHC) molecules in their surface. These cells
mostly migrate to draining lymph nodes, present ApoB100 peptides
to naïve T cells and stimulate their differentiation and expansion into
antigen-specific effector T cells. In the plaque, these effector T cells
will recognize the antigens presented by antigen-presenting cells,
releasing pro-inflammatory cytokines such as IFN-g that contribute
to the development of the lesion [5,6].
There are several subsets of effector T cells with a role in athero-
sclerosis. T helper (Th) CD4+ cells form a major population in the pla-
que next to CD8+ T cells [7]. The different subsets of Th cells might
have completely different roles in the development of atherosclero-
sis. For instance, Th1 cells have a pro-atherogenic effect due to the
secretion of pro-inflammatory cytokines, mainly IFN-g [8]. On the
other hand, T regulatory cells (Tregs) are a subset of Th cells that are
thought to have anti-atherogenic functions as lower frequency and
functional impairment of Tregs have been observed in patients with
coronary artery disease [9,10]. Tregs can suppress effector T cells,
such as Th1 cells, and therefore control inflammatory responses.
The important role of LDL in the initiation of atherosclerotic
lesions, the presence of both auto-reactive T and B cells as well as
anti-oxLDL antibodies has led to the notion of the autoimmune
component of atherosclerosis [11,12]. Interestingly, there is a well-
defined correlation between autoimmune disorders and the
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tis patients have a higher risk of cardiovascular disease and have a
1.5 to 2-times higher rate of cardiovascular events than the general
population [14,15].
The importance of the immune component of atherosclerosis is evi-
denced by the presence of residual cardiovascular risk in a significant
percentage of patients undergoing lipid-lowering therapies, highlight-
ing the need of novel approaches in the treatment of cardiovascular
diseases (CVD) [16].2. Anti-inflammatory therapies in clinical trials
Despite the widespread use of statins, cardiovascular diseases are
still the number 1 cause of death globally. This can be partially
explained by the presence of the significant residual cardiovascular
risk observed in patients even under intensive statin treatment and
low levels of LDL [17]. Randomized clinical trials have shown that the
frequency of cardiovascular events is lower in patients with low lev-
els of high-sensitivity C-reactive protein (hsCRP), a biomarker of
inflammation [18]. These observations suggest that targeting inflam-
mation in atherosclerosis might contribute further to the reduction
in cardiovascular risk [19].
Targeting pro-inflammatory cytokines to reduce the residual
inflammatory risk of cardiovascular events is a strategy that has been
studied in clinical trials. The CANTOS (Canakinumab Antiinflamma-
tory Thrombosis Outcome Study) trial assessed the efficacy of the
anti-IL1b human monoclonal antibody canakinumab to prevent vas-
cular events in patients with previous history of myocardial infarc-
tion and presenting high levels of hsCRP marker. IL-1b, a pro-
inflammatory cytokine, triggers the upregulation of inflammatory
markers and adhesion molecules in endothelial cells, promotes the
recruitment of immune cells to the atherosclerotic plaque and indu-
ces smooth muscle cell proliferation [20,21]. Altogether, this contrib-
utes to the initiation and development of atherosclerosis plaques
[22]. Patients included in the CANTOS trial had undergone aggressive
secondary prevention therapies including high-dose of statins. The
results showed that the treatment with 150 mg of Canakinumab
once every 3 months leads to a 15% reduction in the incidence of
non-fatal myocardial infarction, non-fatal stroke or cardiovascular
death compared to placebo. The results also showed a significant
reduction in the inflammatory biomarkers hsCRP and IL-6 but no
effects on LDL or HDL levels, therefore the clinical benefit could be
attributed to the attenuated inflammation [23]. The results from this
study point out to the importance of targeting the cardiovascular
risk associated to inflammation in addition to the reduction of LDL
cholesterol levels.
Similarly, results from COLCOT (Colchicine Cardiovascular Out-
comes Trial) have shown that low-doses of colchicine (0.5 mg/day), a
potent anti-inflammatory drug, led to a significant reduction in the
risk of death from cardiovascular causes, resuscitated cardiac arrest,
myocardial infarction, stroke and angina compared to the placebo
group [24].
Another approach to target inflammation in atherothrombosis is the
use of low doses of methotrexate. Low-dose methotrexate is already
used in the treatment of certain inflammatory conditions and observa-
tional studies have associated this treatment with lower frequency of
cardiovascular events [25]. However, in the Cardiovascular Inflamma-
tion Reduction Trial (CIRT), low-dose methotrexate did not reduced the
levels of inflammatory biomarkers IL-1b, IL-6 or CRP in patients with
previous history of myocardial infarction or coronary disease and did
not reduced the frequency of nonfatal myocardial infarction, nonfatal
stroke, cardiovascular death or unstable angina [26].
The apparent contradictory results from CANTOS, COLCOT and
CIRT studies highlight the complexity of the inflammatory path-
ways involved and the importance of taking this into considerationwhen designing anti-inflammatory interventions for cardiovascular
diseases.
3. Antigen-specific tolerance in inflammatory and autoimmune
diseases
The presented therapeutic strategies induce a systemic anti-
inflammatory state that can have important side effects in the long
term, such as higher risk of infections, as shown in both the CANTOS
and the COLCOT trials [27,23,24]. An alternative approach to the use
of systemic anti-inflammatory molecules could be the induction of
antigen-specific tolerance towards disease-specific autoantigens.
This approach has been translated into clinical trials for diseases such
as rheumatoid arthritis (RA), type 1 diabetes (T1D) and multiple scle-
rosis (MS), but has not been clinically applied for treatment of CVD.
Lessons learned from these clinical trials can help to advance the
application of this strategy in CVD.
Two main approaches for the induction of antigen-specific
immune tolerance have been studied so far in clinical trials. One is
the administration of tolerogenic dendritic cells (tolDCs) or Tregs
with capacity to induce immune tolerance. Another approach is the
administration of autoantigens at low doses, together with tolero-
genic adjuvants or using tolerogenic administration routes.
An example of the former is a phase I clinical trial that studied the
safety of the administration of tolDCs loaded with autoantigens from
synovial fluid for treatment of RA [28]. For this trial, tolDCs were dif-
ferentiated from peripheral blood mononuclear cells (PBMCs) from
patients in the presence of dexamethasone and vitamin D3 [29].
Safety assessment was made based on the proportion of patients
experiencing flares in the target knee within 5 days after administra-
tion of tolDCs. None of the patients reported aggravated symptoms
indicating that the therapy is safe. Furthermore, an exploratory effi-
cacy assessment showed symptoms resolution in 2 out of 3 patients
receiving the highest cell dose.
In another phase I clinical trial, the safety and biological activity of
autologous tolDCs loaded with the citrullinated peptides relevant for
RA were administered intradermally to RA patients [30]. The safety
of the treatment was confirmed as only mild adverse effects were
detected. Furthermore, the results showed a decrease in the levels of
CRP and pro-inflammatory cytokines and a reduction in the popula-
tion of effector T cells. Unfortunately, clinical efficacy was not evalu-
ated in this trial, mainly due to the low number of patients included
in the trial. This limitation was related to the high costs associated to
the manufacture of autologous tolDCs, one of the main drawbacks of
cell-based therapies.
The administration of autologous tolDC also appeared to be safe
and well-tolerated in a phase I clinical trial in T1D [31]. Safety was
evaluated not only based on the presence of adverse reactions, but
also by measuring the presence in serum of auto-antibodies and cyto-
kines different to those usually present in T1D and following changes
in immune cell populations with flow cytometry. Patients received
intradermal injection of 1 £ 107 cells either not manipulated or dif-
ferentiated into tolDCs. The results from the trial did not show any
noticeable adverse effect on patients, neither significant changes in
immune cell populations.
Another cell-based strategy to induce tolerance is the administra-
tion of Tregs. In a phase I clinical trial for T1D, the administration of
autologous polyclonal Tregs showed that the therapy was well toler-
ated, and no major adverse reactions were observed [32]. Clinical
parameters like c-peptide levels, insulin use and haemoglobin A1c
levels were included as secondary outcomes in the study. However,
due to the reduced number of patients enroled in the study (16
patients in 4 dose cohorts), no assessment of the clinical efficacy of
the treatment could be done. Previous reports have highlighted
potential problems with Treg cell therapies regarding phenotypic
changes in the Tregs, switching from an anti-inflammatory to a
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cells that could aggravate the disease [33,34]. Therefore, in this
study, the stability of the Treg phenotype after in vitro expansion
and the suppressive activity of the Tregs before the administration
had to be closely monitored.
The other approach for the induction of antigen-specific tolerance
is the use of peptides. A clinical trial in RA have studied the efficacy of
tolerance induction towards heat-shock proteins (HSP). HSP are natu-
rally produced by cells under certain stress situations such as inflam-
mation. The release of HSP by stressed cells induces an anti-
inflammatory response mediated by HSP-specific Tregs in order to
control the inflammatory process [35]. In a phase II trial, RA patients
received an oral dose of the HSP40-derived peptide dnaJP1 to induce
mucosal tolerance. The peptide dnaJP1 has been previously identified
as an important T cell epitope in RA [36]. The results showed a signifi-
cant improvement in clinical response, defined by a reduction in
swollen joints, pain, disability and/or acute phase reactant levels, in
the group treated with dnaJP1 compared to placebo. Furthermore,
this improvement was accompanied by a reduced production of pro-
inflammatory TNFa in ex vivo re-stimulated PBMCs [37].
Results of clinical trials for peptide-based treatments in T1D are
also promising. In a phase Ib trial, the intradermal administration of a
proinsulin peptide to T1D patients showed to be safe and well toler-
ated [38]. The results showed a less pronounced loss of insulin pro-
duction capacity in the treatment groups compared to the placebo
group. Consequently, no significant increase in average insulin doses
was observed in the treatment groups while a progressive increase
was seen in the placebo group. Furthermore, treated patients showed
higher levels of anti-inflammatory IL-10 production when CD4+ T
cells were ex vivo stimulated with proinsulin.
In the context of MS, the application of tolerogenic vaccines has
provided mixed results regarding their efficacy and tolerability. A
phase II clinical trial in 2005 showed that the intravenous administra-
tion of the synthetic peptide MBP8298, derived from myelin basic
protein (MBP), had a beneficial effect only in a subgroup of MS
patients presenting HLA haplotypes DR2 and/or DR4. Patients receiv-
ing MBP8298 also showed a reduction in the level of anti-MBP
autoantibodies, indicating tolerization towards the antigen [39].
However, in a phase III trial, the same peptide and dosage failed to
show a significant reduction in disease progression in HLA-DR2+ and/
or HLA-DR4+ patients [40].
Cocktails of different peptides derived from MBP have performed
better in clinical trials. In phase Ib and IIa clinical trials, the adminis-
tration of a cocktail composed of 4 peptides derived from MBP led to
a reduced number of brain lesions compared to baseline. The trial
design included a dose escalation period of 8 weeks, with peptide
doses increasing from 25 mg to 800 mg followed by a full-dose
(800 mg peptide cocktail) period in order to avoid unwanted T cell
activation and systemic pro-inflammatory cytokine release, a com-
mon concern in these peptide-based therapies [41].
Other clinical trials have highlighted the importance of the
administration route for the induction of tolerance. Oral, sublingual,
nasal and dermal administration routes are the most commonly used
due to the natural role of mucosal and skin immunity in tolerance
induction [42]. For instance, the transdermal administration route
has shown to be optimal to induce tolerance towards myelin peptidesTable 1
Main advantages and disadvantages of peptide-based and cell-based strategies for the induc
Peptide-based therapies
Advantages Disadvantages
Lower cost of manufacture HLA genotyping often required
Stable peptide formulations are relatively straight-
forward
Peptides subject to proteolytic deg
Easier administration Dose need to be carefully selectedin MS patients. A clinical trial studied the administration of a mixture
of three peptides derived from MBP, proteolipid protein (PLP) and
myelin oligodendrocyte glycoprotein (MOG), to MS patients using a
transdermal skin patch. Skin biopsies showed an increase in activated
Langerhans cells, a type of antigen-presenting cells found in the skin,
and an increase in DCs in draining lymph nodes in patients receiving
the peptides mixture compared to the placebo group. The treatment
also attenuated the proliferative response of CD4+ T cells, an increased
production of IL-10 and a decrease in IFN-g production upon ex vivo re-
stimulation with the peptides. The study however did not include any
clinical endpoints to assess the effect of the treatment in the progression
of the disease [43].
Overall, the clinical trials have shown that tolerance induction is a
feasible approach that can attenuate some of the pro-inflammatory
responses present in diseases such as RA, T1D or MS but they have
also shown the limitations of both peptide-based and cell-based ther-
apies (Table 1). Peptide-based approaches present advantages such as
relatively straight-forward development of stable formulations of
peptides thanks to the extensive work carried out in the formulation
of subunit vaccines for infectious disease as well as the lower cost of
manufacture compared to cell-based therapies and often admit more
convenient administration routes such as oral or intradermal. But
this strategy also presents some disadvantages, for instance the dose
should be carefully selected as too high doses can induce unwanted
pro-inflammatory responses while too low doses will not have the
desired tolerogenic effect. Furthermore, the proteolytic degradation
of the peptide in biological fluids should also be taken into account
when choosing the peptide dose. Lastly, appropriate HLA-peptide
interaction is a prerequisite for the effectivity of peptide-based
immunotherapies therefore HLA typing of patients is often required
in this type of therapies, as described in the clinical trial with
MBP8298 peptide [39]. The main advantage of cell-based therapies is
that the administration of tolDCs or Tregs can directly induce
immune tolerance through expansion of antigen-specific Tregs or
induction of anergy in effector T cells, respectively. However, these
therapies often involve the isolation of autologous cells from patients,
the induction of a tolerogenic phenotype ex vivo and the subsequent
reinfusion to the patient, which is costly and time-consuming [44].
Furthermore, there are concerns over the variability and stability of
the tolerogenic phenotype induced ex vivo.
The formulation of peptide-based vaccines is crucial not only for
stability of the peptide but also for the induction of tolerance. The use
nanoparticles as delivery systems for immune modulation is cur-
rently under investigation and has the potential to overcome some of
the problems associated with peptide and cell-based therapies. For
instance, the delivery of peptides using nanoparticles can prevent
degradation by proteases in biological fluids, allow the specific deliv-
ery to target cells such as DCs, include tolerogenic adjuvants to
induce the desired tolerogenic phenotype in vivo and these nanopar-
ticle formulations can be manufacture in high volumes at lower cost
than cell-based therapeutics.
4. Tolerogenic vaccines in atherosclerosis
Despite the strong evidence supporting the role of inflammation
and autoimmunity in the development of atherosclerosis, to the besttion of tolerance.
Cell-based therapies
Advantages Disadvantages
Direct tolerance induction Expensive and time-consuming manufacture
radation Variability of tolerogenic phenotype
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safety, tolerability, feasibility or efficacy of antigen-specific tolerance
induction to halt the development of atherosclerosis.
One of the obstacles in the development of vaccines for ath-
erosclerosis is the lack of well-defined epitopes responsible for
the initiation and maintenance of the inflammatory responses in
atherosclerosis. However, several reports have shown that the
induction of tolerance towards oxLDL and HSP attenuate athero-
sclerosis in pre-clinical models [4547]. Therefore peptides
derived from ApoB100 or HSP have been the main focus of atten-
tion in the search of relevant epitopes in atherosclerosis.
Oral administration of oxLDL or malondialdehyde-treated LDL
induced Treg-mediated tolerance in LDLr/ mice, accompanied by a
significant reduction in atherosclerotic lesions initiation and progres-
sion [46]. This report indicates the potential of ApoB100-derived anti-
gens as candidates for peptide-based vaccination strategies in
atherosclerosis. Immunization of LDLr/ (LDLrtm1Her) mice express-
ing human ApoB100 with P210 (human ApoB1003136-3155) has shown
to reduce atherosclerosis in pre-clinical studies and the mechanism
of action of this therapeutic strategy has been related to the induction
of Tregs. The administration of peptide P45 (human ApoB100661-680)
or P210 together with alum salts adjuvant has shown to reduce the
area of atherosclerotic plaques by 66 and 55% respectively compared
to control. The authors also speculate with the activation of Tregs as
the mechanism of action mediating this anti-atherogenic effect
[48,49]. In another study, the administration of P210 without any
adjuvant led to a 30% reduction in plaque size compared to control
group and abrogated the growth of advanced atherosclerotic lesions.
Furthermore, this effect was associated with a 30% increase in the
Treg frequency in lymph nodes and Treg depletion abolished the
atheroprotective effect of the immunization [50].
The immunization with peptide P6 (ApoB100978-992) together
with Complete Freund’s adjuvant (CFA) has shown to promote ath-
erosclerosis in murine models while the same peptide can have
atheroprotective effects when administered with a different immuni-
zation regime consisting in a prime immunization with P6 in CFA fol-
lowed by 4 booster immunization with Incomplete Freund’s
Adjuvant (IFA), known to induce suppressive immune responses
[5153]. The same P6 peptide in combination with the squalene oil-
based adjuvant Addavax also induced a 52% reduction in aortic lesion
area in ApoE-/ mice compared to peptide alone [54]. These results
highlight the importance of the careful selection of adjuvants to
achieve atheroprotection.
The selection of atheroprotective peptides to be used in a tolero-
genic vaccine should also consider the binding affinity to different
HLA haplotypes. Peptides that can bind to a wide range of HLA haplo-
types, such as peptides P265 and P295 from human ApoB100
described by Gistera et al. would cover most of the world population
[55]. Similarly, peptide P18 (human ApoB1003030-3044) was identified
in silico and in vitro as a strong binder to the most common HLA-DR
haplotypes. Immunization of ApoE/ mice with P18 showed an
induction of Tregs and a 35% reduction in atherosclerosis lesion size
[56]. These studies underline the importance of taking into account the
wide variability of HLA haplotypes from early phases of pre-clinical
research.
The use of nanoparticles with intrinsic tolerogenic capacity, such
as specific liposomal formulations, to deliver ApoB100 peptides has
also shown promising results in murine models of atherosclerosis.
The use of a liposomal formulation containing 1,2-distearoyl-sn‑gly-
cero-3-phosphoglycerol (DSPG) to deliver the peptide P3500
(ApoB1003500-3514), similar to P3 peptide (ApoB1003501-3515) previ-
ously reported to induce atheroprotection by Ley group, showed to
reduce lesion size by 50% compared to control [57,52].
Other antigen candidates for immunomodulatory vaccines for
atherosclerosis are HSP-derived peptides. These proteins are over-
expressed under cellular stress and they are involved in severalinflammatory and autoimmune diseases including atherosclerosis
[58,59]. HSP-specific Tregs could halt inflammation in atherosclerosis
in a by-stander manner due to the constitutive over-expression of
HSP in inflamed tissue. Therefore, the induction of HSP-specific Tregs
could circumvent the problem of the lack of well-defined primary
antigenic trigger in atherosclerosis [35]. Vaccination studies with
HSP have provided mixed results, with some showing an increase in
atherosclerosis upon immunization while others showed an anti-ath-
erogenic effect [6064]. A key difference between these studies
might be the adjuvant used. In the studies showing a pro-atherogenic
effect of HSP immunization, the protein was administered together
with CFA or IFA. Contrarily, the studies showing an anti-atherogenic
effect of the immunization with HSP proteins or peptides either use
tolerogenic adjuvants, such as the combination of alum salts and
anti-CD45RB antibodies, or are administered without adjuvants, and
the effects have been linked to the induction of Tregs. Therefore, the
election of the appropriate adjuvants and administration route to
promote tolerance seems to be critical.
Overall, pre-clinical data supports effectiveness of tolerance
induction towards atherosclerosis-relevant peptides to halt the
development of atherosclerosis. The delivery of these antigens in the
absence of TLR stimulation or in the presence of molecules that pro-
mote tolerance, can induce the expansion of Tregs and reduce the
pro-inflammatory responses in atherosclerosis [50,54].
Most of the studies have focused on arresting the development of
growing atherosclerotic plaques, however the majority of clinical
manifestations of atherosclerosis occur at advanced stages of the dis-
ease. Therefore, the induction of atherosclerosis lesion regression
and/or plaque stabilization is clinically most relevant. The potential
of Tregs to induce plaque regression and stabilization has been
shown in pre-clinical animal models. It has been reported that the
administration of CD3 antibodies combined with a reduction in non-
HDL cholesterol levels can increase the Treg to effector T cells ratio
and induce 25% regression in plaque size in a mouse model of athero-
sclerosis. Furthermore, this effect was abolished upon Treg depletion,
indicating a critical role of Tregs in the atherosclerosis regression
[65]. In another study, Tregs were induced in a LDLr/ mouse model
by administration of a IL-2 and anti-IL-2 antibody complex, achieving
a 10-fold increase in Tregs. This Treg expansion led to stabilization of
advanced atherosclerotic lesions established before starting the treat-
ment [66]. These results show the potential of tolerogenic vaccines
inducing Tregs expansion to stabilize and prompt regression of ath-
erosclerotic lesions.
5. Clinical translation
Despite considerable pre-clinical research carried out in the field
of tolerogenic vaccination for atherosclerosis, the promise of an ath-
erosclerosis vaccine remains unfulfilled. There are several challenges
in the translation from pre-clinical models to clinical trials. First of
all, the animal models to study atherosclerosis present important dif-
ference with the human situation. For instance, ApoB expressed in
mice undergoes different post-translational modifications and has a
different structural conformation than human-expressed ApoB, and
therefore can trigger different immune responses [67]. Furthermore,
the immune system of mice presents considerable differences with
human, such as several cytokines and immune receptors [68]. The
use of humanized mice that resemble more closely the human situa-
tion, for instance expressing human ApoB100 or with humanized
immune system, can overcome some of these challenges [48,69].
A prerequisite for the clinical translation of this therapeutic strat-
egy is the selection of antigen or antigens for vaccination. It is not
clear whether there is a common driving antigen for all HLA haplo-
types in atherosclerotic patients. Furthermore, specific subtypes of
HLA, such as HLA-DRB1£01, have been associated with increased
risk of coronary artery disease and myocardial infarction [70]. This
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it might be interesting to select peptides with strong binding affinity
for those HLA haplotypes more prevalent in atherosclerosis patients.
Therefore, it is yet to be determined if a broadly applicable vaccine
can be developed or a personalized strategy should be followed
instead.
The selection of the vaccine formulation is another important
point to carefully consider. Initially, the most obvious formulations
would include the peptide or peptides and the appropriate adjuvants,
resembling formulations of subunit vaccines that have been widely
investigated. Further developments should include nanoparticle
formulations such as delivery systems with intrinsic tolerogenic
capacity [57].
The next step is the design of clinical trials for a tolerogenic vac-
cine strategy and this will require a careful selection of the target
population. Should only patients with high inflammatory risk be
admitted or should any patient with clinically confirmed atheroscle-
rosis be eligible? For this decision we should consider what design
will better show the potential for this therapeutic approach. For
instance, patients presenting high inflammatory risk would poten-
tially benefit the most from the therapy and perhaps should be the
focus of the first trials.
Finally, another parameter that can be challenging is the selection
of the endpoints of the clinical trials. This requires the definition of
biomarkers for atherosclerotic progression, regression and cardiovas-
cular risk. The assessment of the atherosclerotic plaque morphology,
size or parameters related to plaque stability could be done using
imaging techniques such as tomography, however this would repre-
sent a significant technical challenge in large clinical studies. Due to
the immune-modulating nature of the therapeutic approach, the
monitoring of both humoral and cellular adaptive immune responses,
as well as the antigen-specificity of those responses would be neces-
sary. Furthermore, the levels of inflammatory biomarkers like CRP or
pro-inflammatory cytokines like IL-6 or IL-1b, have shown to be
good predictors of cardiovascular risk and should be used to monitor
the efficacy of an atherosclerosis vaccine [71].
6. Conclusions
Cardiovascular diseases and their main underlying pathology, ath-
erosclerosis, remain amongst the top causes of mortality globally.
High levels of LDL cholesterol were once considered the only driving
force underlying the formation and progression of atherosclerotic
plaques. However, despite the broad use of lipid-lowering therapies,
a significant proportion of patients remains at risk for cardiovascular
complications. Recent evidence shows the importance of inflamma-
tion and a possible autoimmune component in the aetiology of ath-
erosclerosis, but no therapies have been developed yet to target this
key component of the disease. The induction of immune tolerance
towards the self-antigens driving the deleterious immune responses
in atherosclerosis is a promising new strategy. This can be achieved
by inducing antigen-specific Tregs, which have the capacity to arrest
pro-inflammatory responses and restore immune balance. In certain
aspects, atherosclerosis resembles other inflammatory and autoim-
mune diseases like rheumatoid arthritis, multiple sclerosis or type 1
diabetes therefore the lessons learnt in clinical trials of immune mod-
ulating vaccines for these diseases can be used to advance in the
development of similar strategies for atherosclerosis. Although there
are still challenges to overcome in the clinical translation of pre-clini-
cal results, immune-modulating vaccines for atherosclerosis can rep-
resent a leap forward in the treatment of CVD.
7. Outstanding questions
There are several questions that still need to be addressed in order
to advance in the clinical development of tolerogenic vaccines forcardiovascular disease. To start, it is still not clear what aspects and
how should we improve pre-clinical models to test the efficacy of
this therapeutic approach and facilitate clinical translation.
Regarding the design of vaccine formulations for tolerance induc-
tion, the most optimal tolerogenic adjuvant for human use still needs
to be defined.
On the other hand, there are still aspects of immune responses in
atherosclerosis that need to be elucidated, for example, is there a sin-
gle antigenic determinant driving immune response? The answer to
this question will determine if we can develop a widely applicable
tolerogenic vaccine or if we should follow a personalised strategy
instead.
Related to the design of clinical trials, the preferred target popula-
tion for a tolerogenic vaccine against atherosclerosis needs to be
determined as well as the endpoints of these studies. Should this
strategy be aimed only to patients with high-inflammatory risk or to
the general population of atherosclerosis patients? Can we design
large-scale clinical trials with endpoints that rely not only on general
markers of cardiovascular disease but also on plaque morphology
and immunophenotyping?
8. Search strategy and selection criteria
References for this review were identified using PubMed data-
base. Only references related to clinical trials were included for the
search terms “rheumatoid arthritis”, “multiple sclerosis”, “type 1 dia-
betes” in combination with “vaccine”, “tolerogenic vaccine”, “T regu-
latory cells”, “tolerogenic dendritic cells”. Other search terms used
were “atherosclerosis”, “cardiovascular disease” in combination with
“vaccination”, “tolerance”, “immune response”, “antigens”, “T regula-
tory cells”, “tolerogenic dendritic cells” “nanoparticles”, “adjuvants”.
For this second part the search was not limited to clinical trials. Only
articles published in English were included with preference for
articles published in the past 10 years.
Authors contribution
FLV, JK and BS designed the concept and outline of original draft.
FLV wrote the original manuscript, JK and BS reviewed and supported
the editing of the original manuscript. FLV, BS and JK edited final
manuscript.
Declaration of Competing Interest
The authors have nothing to disclose.
Funding
FLV is supported by Health Holland and Samen Werkende
Gezondheidsfondsen (SGF), grant no. LSHM18056-SGF. The funding
source had no role in the preparation of this manuscript.
References
[1] Herrington W, Lacey B, Sherliker P, Armitage J, Lewington S. Epidemiology of ath-
erosclerosis and the potential to reduce the global burden of atherothrombotic
disease. Circ Res 2016;118:535–46.
[2] Libby P, Ridker PM, Hansson GK. Inflammation in atherosclerosis. J Am Coll Car-
diol 2009;54:2129–38.
[3] Gistera A, Hansson GK. The immunology of atherosclerosis. Nat Rev Nephrol
2017;13:368–80.
[4] Orekhov AN, Chistiakov DA, Grechko AV, Melnichenko AA, Myasoedova VA.
Mechanisms of foam cell formation in atherosclerosis. J Mol Med 2017;95:
1153–65.
[5] Witztum JL, Lichtman AH. The influence of innate and adaptive immune
responses on atherosclerosis. Annu Rev Pathol Mech Dis 2014;9:73–102.
[6] Stemme S, et al. T lymphocytes from human atherosclerotic plaques recognize
oxidized low density lipoprotein. Proc Natl Acad Sci 1995;92:3893–7.
6 F.L. Vigario et al. / EBioMedicine 57 (2020) 102827[7] van Duijn J, Kuiper J, Sl€utter B. The many faces of CD8+ T cells in atherosclerosis.
Curr Opin Lipidol 2018:1. doi: 10.1097/MOL.0000000000000541.
[8] Gr€onberg C, Nilsson J, Wigren M. Recent advances on CD4 + T cells in atheroscle-
rosis and its implications for therapy. Eur J Pharmacol 2017:1–9. doi: 10.1016/j.
ejphar.2017.04.029.
[9] Zhu Z, et al. Function of T regulatory type 1 cells is down-regulated and is associ-
ated with the clinical presentation of coronary artery disease. Hum Immunol
2018;79:564–70.
[10] Hasib L, Lundberg AK, Zachrisson H, Ernerudh J, Jonasson L. Functional and
homeostatic defects of regulatory T cells in patients with coronary artery disease.
J Intern Med 2016;279:63–77.
[11] Wolf D, Ley K. Immunity and inflammation in atherosclerosis. Circ Res
2019;124:315–27.
[12] Fredrikson GN, et al. Identification of immune responses against aldehyde-modi-
fied peptide sequences in apoB associated with cardiovascular disease. Arterios-
cler Thromb Vasc Biol 2003;23:872–8.
[13] Sanjadi M, et al. Atherosclerosis and autoimmunity: a growing relationship. Int J
Rheum Dis 2018;21:908–21.
[14] Crowson CS, et al. Rheumatoid arthritis and cardiovascular disease. Am Heart J
2013;166:622–8 e1.
[15] Blum A, Adawi M. Rheumatoid arthritis (RA) and cardiovascular disease. Autoim-
mun Rev 2019. doi: 10.1016/j.autrev.2019.05.005.
[16] Ridker PM. Clinician’s Guide to Reducing Inflammation to Reduce Atherothrom-
botic Risk. J Am Coll Cardiol 2018;72:3320–31.
[17] Murphy SA, Cannon CP, Wiviott SD, McCabe CH, Braunwald E. Reduction in recur-
rent cardiovascular events with intensive lipid-lowering statin therapy compared
with moderate lipid-lowering statin therapy after acute coronary syndromes. J
Am Coll Cardiol 2009;54:2358–62.
[18] Li Y, et al. Hs-CRP and all-cause, cardiovascular, and cancer mortality risk: a meta-
analysis. Atherosclerosis 2017;259:75–82.
[19] Ridker PM, et al. C-reactive protein levels and outcomes after statin therapy. N
Engl J Med 2005;352:20–8.
[20] Bevilacqua MP, Pober JS, Wheeler ME, Cotran RS, Gimbrone MA. Interleukin-1
activation of vascular endothelium. Effects on procoagulant activity and leukocyte
adhesion. Am J Pathol 1985;121:394–403.
[21] Eun SY, Ko YS, Park SW, Chang KC, Kim HJ. IL-1b enhances vascular smooth mus-
cle cell proliferation and migration via P2Y2 receptor-mediated RAGE expression
and HMGB1 release. Vascul Pharmacol 2015;72:108–17.
[22] Libby P. Interleukin-1 beta as a target for atherosclerosis therapy. J Am Coll Car-
diol 2017;70:2278–89.
[23] Ridker PM, et al. Antiinflammatory therapy with canakinumab for atherosclerotic
disease. N Engl J Med 2017;377:1119–31.
[24] Tardif J-C, et al. Efficacy and safety of low-dose colchicine after myocardial infarc-
tion. N Engl J Med 2019;381:2497–505.
[25] Micha R, et al. Systematic review and meta-analysis of methotrexate use and risk
of cardiovascular disease. Am J Cardiol 2011;108:1362–70.
[26] Ridker PM, et al. Low-dose methotrexate for the prevention of atherosclerotic
events. N Engl J Med 2019;380:752–62.
[27] Bernatsky S, Hudson M, Suissa S. Anti-rheumatic drug use and risk of serious infec-
tions in rheumatoid arthritis. RheumatologyRheumatology 2007;46:1157–60.
[28] Bell GM, et al. Autologous tolerogenic dendritic cells for rheumatoid and inflam-
matory arthritis. Ann Rheum Dis 2017;76:227–34.
[29] Harry RA, Anderson AE, Isaacs JD, Hilkens CMU. Generation and characterisation
of therapeutic tolerogenic dendritic cells for rheumatoid arthritis. Ann Rheum Dis
2010;69:2042–50.
[30] Dudek NL, et al. Citrullinated peptide dendritic cell immunotherapy in HLA risk
genotypepositive rheumatoid arthritis patients. Sci Transl Med 2015;7
290ra87-290ra87.
[31] Giannoukakis N, Phillips B, Finegold D, Harnaha J, Trucco M. P.hase I (safety) study
of autologous tolerogenic dendritic cells in type 1 diabetic patients. Diabetes Care
2011;34:2026–32.
[32] Bluestone JA, et al. Type 1 diabetes immunotherapy using polyclonal regulatory T
cells. Sci Transl Med 2015;7 315ra189-315ra189.
[33] Putnam AL, et al. Expansion of human regulatory T-cells from patients with type 1
diabetes. Diabetes 2009;58:652–62.
[34] Kmieciak M, et al. Human T cells express CD25 and Foxp3 upon activation and
exhibit effector/memory phenotypes without any regulatory/suppressor func-
tion. J Transl Med 2009;7:89.
[35] van Eden W. Immune tolerance therapies for autoimmune diseases based on heat
shock protein T-cell epitopes. Philos Trans R Soc B Biol Sci 2018;373.
[36] Albani S, et al. Positive selection in autoimmunity: abnormal immune responses
to a bacterial dnaJ antigenic determinant in patients with early rheumatoid
arthritis. Nat Med 1995;1:448–52.
[37] Koffeman EC, et al. Epitope-specific immunotherapy of rheumatoid arthritis: clin-
ical responsiveness occurs with immune deviation and relies on the expression of
a cluster of molecules associated with T cell tolerance in a double-blind, placebo-
controlled, pilot phase II tria. Arthritis Rheum 2009;60:3207–16.
[38] Alhadj Ali M, et al. Metabolic and immune effects of immunotherapy with proin-
sulin peptide in human new-onset type 1 diabetes. Sci Transl Med 2017;9:
eaaf7779.
[39] Warren KG, Catz I, Ferenczi LZ, Krantz MJ. Intravenous synthetic peptide
MBP8298 delayed disease progression in an HLA Class II-defined cohort of
patients with progressive multiple sclerosis: results of a 24-month double-blindplacebo-controlled clinical trial and 5 years of follow-up treatment. Eur J Neurol
2006;13:887–95.
[40] Freedman MS, et al. A phase III study evaluating the efficacy and safety of
MBP8298 in secondary progressive MS. Neurology 2011;77:1551–60.
[41] Chataway J, et al. Effects of ATX-MS-1467 immunotherapy over 16 weeks in
relapsing multiple sclerosis. Neurology 2018;90:e955–62.
[42] Tlaskalova-Hogenova H, et al. Commensal bacteria (normal microflora), mucosal
immunity and chronic inflammatory and autoimmune diseases. Immunol Lett
2004;93:97–108.
[43] Jurynczyk M, et al. Immune regulation of multiple sclerosis by transdermally
applied myelin peptides. Ann Neurol 2010;68:593–601.
[44] Yoo S, Ha S-J. Generation of tolerogenic dendritic cells and their therapeutic appli-
cations. Immune Netw 2016;16:52.
[45] Palinski W, Miller E, Witztum JL. Immunization of low density lipoprotein (LDL)
receptor-deficient rabbits with homologous malondialdehyde-modified LDL
reduces atherogenesis. Proc Natl Acad Sci 1995;92:821–5.
[46] van Puijvelde GHM, et al. Induction of oral tolerance to oxidized low-density lipo-
protein ameliorates atherosclerosis. Circulation 2006;114:1968–76.
[47] van Puijvelde GHM, et al. Induction of oral tolerance to HSP60 or an HSP60-pep-
tide activates T cell regulation and reduces atherosclerosis. Arterioscler Thromb
Vasc Biol 2007;27:2677–83.
[48] Fredrikson GN, Bj€orkbacka H, S€oderberg I, Ljungcrantz I, Nilsson J. Treatment with
apo B peptide vaccines inhibits atherosclerosis in human apo B-100 transgenic
mice without inducing an increase in peptide-specific antibodies. J Intern Med
2008;264:563–70.
[49] Wigren M, et al. Evidence for a role of regulatory T cells in mediating the athero-
protective effect of apolipoprotein B peptide vaccine. J Intern Med
2011;269:546–56.
[50] Herbin O, et al. Regulatory T-cell response to apolipoprotein B100derived pepti-
des reduces the development and progression of atherosclerosis in mice. Arte-
rioscler Thromb Vasc Biol 2012;32:605–12.
[51] Shaw MK, et al. T-cells specific for a Self-Peptide of ApoB-100 exacerbate aortic
atheroma in murine atherosclerosis. Front Immunol 2017;8.
[52] Tse K, et al. Atheroprotective vaccination with MHC-II restricted peptides from
ApoB-100. Front Immunol 2013;4:1–10.
[53] Zamora A, Matejuk A, Silverman M, Vandenbark AA, Offner H. Inhibitory effects of
incomplete Freund’s adjuvant on experimental autoimmune encephalomyelitis.
Autoimmunity 2002;35:21–8.
[54] Kobiyama K, et al. A clinically applicable adjuvant for an atherosclerosis vaccine in
mice. Eur J Immunol 2018;48:1580–7.
[55] Gistera A, et al. Vaccination against T-cell epitopes of native ApoB100 reduces
vascular inflammation and disease in a humanized mouse model of atherosclero-
sis. J Intern Med 2017;281:383–97.
[56] Kimura T, et al. Regulatory CD4+ T cells recognize major histocompatibility com-
plex class II molecule-restricted peptide epitopes of apolipoprotein B. Circulation
2018;138:1130–43.
[57] Benne N, et al. Anionic 1,2-distearoyl-sn-glycero-3-phosphoglycerol (DSPG) lipo-
somes induce antigen-specific regulatory T cells and prevent atherosclerosis in
mice. J Control Release 2018;291:135–46.
[58] Sedlackova L, Nguyen TTH, Zlacka D, Sosna A, Hromadnikova I. Cell surface and
relative mRNA expression of heat shock protein 70 in human synovial cells. Auto-
immunity 2009;42:17–24.
[59] Almanzar G, et al. Autoreactive HSP60 epitope-specific T-cells in early human
atherosclerotic lesions. J Autoimmun 2012;39:441–50.
[60] George J, et al. Enhanced fatty streak formation in C57BL/6J mice by immuni-
zation with heat shock protein-65. Arterioscler Thromb Vasc Biol
1999;19:505–10.
[61] Xu Q, et al. Induction of arteriosclerosis in normocholesterolemic rabbits by
immunization with heat shock protein 65. Arterioscler Thromb A J Vasc Biol
1992;12:789–99.
[62] Klingenberg R, Ketelhuth DFJ, Strodthoff D, Gregori S, Hansson GK. Subcutaneous
immunization with heat shock protein-65 reduces atherosclerosis in Apoe/
mice. Immunobiology 2012;217:540–7.
[63] Long J, et al. Nasal immunization with different forms of heat shock protein-65
reduced high-cholesterol-diet-driven rabbit atherosclerosis. Int Immunopharma-
col 2012;13:82–7.
[64] Zhong Y, et al. Intranasal immunization with heat shock protein 60 induces
CD4 + CD25 + GARP + and type 1 regulatory T cells and inhibits early atherosclero-
sis. Clin Exp Immunol 2016;183:452–68.
[65] Kita T, et al. Regression of atherosclerosis with anti-CD3 antibody via augmenting
a regulatory T-cell response in mice. Cardiovasc Res 2014;102:107–17.
[66] Foks AC, et al. Differential effects of regulatory T cells on the initiation and regres-
sion of atherosclerosis. Atherosclerosis 2011;218:53–60.
[67] Wang X, et al. Immunochemical evidence that human apoB differs when
expressed in rodent versus human cells. J Lipid Res 2003;44:547–53.
[68] Mestas J, Hughes CCW. Of Mice and Not Men: differences between Mouse and
Human Immunology. J Immunol 2004;172:2731–8.
[69] Proto JD, et al. Hypercholesterolemia induces T cell expansion in humanized
immune mice. J Clin Invest 2018;128:2370–5.
[70] Paakkanen R, et al. Proinflammatory HLA-DRB1£01-haplotype predisposes to ST-
elevation myocardial infarction. Atherosclerosis 2012;221:461–6.
[71] Soeki T, Sata M. Inflammatory biomarkers and atherosclerosis. Int Heart J
2016;57:134–9.
